LBT 999

Molecule in Development
LBT molecule

Parkinson's disease

Neurodegenerative diseases impact millions of people worldwide and one of the most common pathologies is Parkinson’s disease. 2% of the total population aged 60 years and above has Parkinson’s disease, but more 10% of the total population has already developed the illnesses as early as the age of 40.

Today, when essential tremors appear, SPECT imaging is used for the diagnostic of Parkinson’s disease, before pathognomonic signs appear.

But SPECT imaging’s low resolution and sensibility as well as its limited quantification capabilities do not facilitate early diagnostics of younger patients. Also its acquisition time being fairly long it impacts negatively both patients and hospitals.

LBT999 is a PET imaging drug candidate which provides high resolution and high sensibility images, in considerably shorter period of time.


  • Patients with essential tremors and a suspicion of Parkinson’s disease


  • US incidence : 50k new patients per year
  • US prevalence : 750k
  • France incidence : 25k new patients per year
  • France prevalence : 166k

Next Generation Cdx Pipeline for Molecular

Find out more about what’s coming in CDx imaging